# Modified bio-Bentall operation with a rapid deployment valve

## TL;DR

A modified bio-Bentall operation using a rapid deployment valve shows promising early results in high-risk patients, with good survival rates and few complications.

## Contribution

The paper presents initial clinical experience with a modified bio-Bentall operation using a rapid deployment valve in high-risk patients.

## Key findings

- No early mortalities or reoperations were observed in 11 patients.
- The 1-year and 3-year survival rates were 90.9% and 54.5%, respectively.
- Two patients required extracorporeal membrane oxygenation and three required permanent pacemaker insertion.

## Abstract

To evaluate the early outcomes of a modified bio-Bentall operation using a rapid deployment valve (RDV) in high-risk patients, focusing on procedural efficacy, survival rates, and complications.

A retrospective review of 11 consecutive patients who underwent the modified bio-Bentall operation with an RDV between January 2018 and December 2022 was conducted. Kaplan–Meier survival analysis was used to determine survival rates. Patients' baseline characteristics, operative details, and postoperative outcomes were reviewed.

The median patient age was 71 years. Most patients presenting with high-risk conditions and significant comorbidities, including inflammatory conditions, chronic lung diseases, and advanced cardiac dysfunction. The median EuroSCORE II was 10.03%. The median aortic cross-clamping and cardiopulmonary bypass times were 73.0 minutes and 99.0 minutes, respectively. No early mortalities or reoperations occurred. Two patients (14.3%) required extracorporeal membrane oxygenation support because of low cardiac output and arrhythmias, and 3 patients (23.1%) required permanent pacemaker insertion. No paravalvular leakage or valve detachment was observed during follow-up. The 1-year survival rate was 90.9%, and the 3-year survival rate was 54.5%. Six patients died during a median follow-up of 35 months, from causes including respiratory complications, gastric cancer, and undetermined factors.

Our initial experience with the modified bio-Bentall operation using an RDV shows favorable early outcomes in relatively high-risk patients. Further validation with larger datasets and long-term follow-up is needed to validate these results.